Company Overview and News

 
Rakesh Jhunjhunwala loads up DHFL shares amid bloodbath in NBFC stock in September quarter

2018-10-15 financialexpress
Amid wild sell-offs and panic in the NBFC space, ace investor Rakesh Jhunjhunwala loaded up on DHFL shares, which plunged by more than 72% from their 52-week highs in the quarter. Notably, Rakesh Jhunjhunwala has increased his stake in Dewan Housing Finance Corporation Ltd to 3.19% as at the end of September quarter, from 2.8% earlier, implying a rise of 0.39%. Notably, Rakesh Jhunjhunwala now holds 1 crore shares of DHFL shares.
501150 HDFCNIFETF DHFL 511413 CENTRUM 511072 CREST 539516 511333 VLSFINANCE

1
Macquarie, Atlantia, Brookfield look to bid for 586.55 km toll roads

2018-10-11 livemint
Mumbai: Macquarie Group, Canada’s Brookfield Asset Management Inc. and Italy’s infrastructure investment firm Atlantia SpA are looking to bid for the second round of auction for toll-operate-transfer rights (TOT) of public road projects, said two people aware of the development. The three companies are in the process of conducting due diligence on the assets, which have been put up for auction by the National Highways Authority of India (NHAI), said the people cited above, requesting anonymity.
501150 BAMGF MQBKY ATASY CENTRUM MCQEF MQG BAMKF ATASF BAM

 
Centrum Capital Limited - Allotment of ESOP/ESPS

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

 
RCom, BEL, Centrum Capital, Indiabulls Housing top gainers among BSE Group A stocks

2018-09-26 moneycontrol
The Indian stock market this Wednesday afternoon continues to remain in the red with the Nifty50 is up down 22 points and is trading at 11,045 while the Sensex is trading lower by 140 points at 36,511.
BHQRY CENTRUM CREST IDKQY HIN 532712 501150 535789 IBULHSGFIN 511413 RCOM 500049 500185 BEL HCC

 
Centrum Capital Limited - Updates

2018-09-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

 
Inventia Healthcare files Rs 450-cr IPO papers with SEBI

2018-09-21 thehindubusinessline
Inventia Healthcare has filed draft papers with the Securities and Exchange Board of India to raise an estimated Rs 450 crore through an initial public offering.
501150 CENTRUM

 
Centrum acquires L&T Finance’s supply chain business

2018-09-05 livemint
MUMBAI: Centrum Financial Services Ltd, the NBFC arm of the Centrum Group, on Wednesday said that it had acquired the supply chain business of L&T Finance.
501150 CENTRUM

 
Centrum Capital Limited - Acquisition

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

 
Centrum Capital Limited - Press Release

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

 
Centrum Capital Limited - Reply to Clarification Sought

2018-09-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

 
Centrum Capital Limited - Shareholders meeting

2018-08-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

 
Centrum Capital Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...